cvs caremark glp 1 coverage MinuteClinic® Weight Loss Program, which may include GLP-1 FDA approved medications CVS Caremark will cover Lilly's

doi: 10.1016/j.neuropharm.2019.107813 [DOI] [PubMed] [Google Scholar] 187

Currently available pharmacotherapeutics options in HF mostly remain focused on HFrEF, where treatments strategies aim at relief of symptoms, improving quality of life, and prolonging the life of the affected individual (McDonagh et al., 2021

However, GLP-1 medications remained relatively niche until Wegovy's approval in June 2021, which sparked the explosive popularity surge in weight loss applications

doi: 10.1016/j.peptides.2024.171212 Summary Keywords GIP -glucose-dependent insulinotropic polypeptide, antagonism, obesity, diabetes, pharmacology Citation Koefoed-Hansen F, Helsted MM, Kizilkaya HS, Lund AB, Rosenkilde MM and Gasbjerg LS (2025) The evolution of the therapeutic concept GIP receptor antagonism

Eleven of the nineteen studies included in this systematic review had a randomized, double-blind placebo-controlled study design [9,17,18,21,22,23,29,30,31,32,33], one study had a single-center open-label comparative study design [24], one study had a prospective design [26], one study had a prospective single-center parallel-group design [28], one study had a prospective randomized study design [27], one study had a prospective randomized placebo-controlled study design [25], one study had an interventional casecontrol study design [35], one study was a prospective analysis [36], and one study had a matched group design [34]